Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
- Registration Number
- NCT00146328
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 997
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 1 Tipranavir Patients With Varying Degrees of Tipranavir Treatment Experience Group 2 Tipranavir Highly Tipranavir Treatment Experienced Patients Group 3 Tipranavir Tipranavir Treatment Naive Patients
- Primary Outcome Measures
Name Time Method Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Carbon Dioxide End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Bilirubin, Total End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Platelets End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Sodium End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Potassium End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Calcium End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Triglycerides End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Uric Acid End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Haemoglobin End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - White Blood Cell ct. End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Phosphate End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alkaline Phosphatase End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Amylase End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatine Phosphokinase End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Lipase End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Glucose End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Cholesterol, Total End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatinine End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Prothrombin Time End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Aspartate Aminotransferase (AST/GOT,SGOT) End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alanine Aminotransferase (ALT/GPT,SGPT) End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Albumin End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 -Low-density Lipoprotein (LDL) End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Number of Patients With Adverse Events Leading to Death End of Trial (>288 weeks) NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) Viral Load - Last Observation Carried Forward (LOCF) Baseline to 192-240 week time interval Change from baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) viral load with last observation carried forward (LOCF)
Change From Baseline in CD4 Cell Count (LOCF) Baseline to 192-240 week time interval Change from baseline in CD4 cell count with last observation carried forward(LOCF).
Trial Locations
- Locations (233)
1182.17.26 Boehringer Ingelheim Investigational Site
🇺🇸Columbus, Ohio, United States
1182.17.89 Boehringer Ingelheim Investigational Site
🇺🇸Berkeley, California, United States
1182.17.73 Boehringer Ingelheim Investigational Site
🇺🇸Los Angeles, California, United States
1182.17.67 Boehringer Ingelheim Investigational Site
🇺🇸Baltimore, Maryland, United States
1182.17.906 Infectious Diseases & HIV - St. Michael's Hospital
🇨🇦Toronto, Ontario, Canada
1182.17.907 University Health Network - Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
1182.17.70 Boehringer Ingelheim Investigational Site
🇺🇸Chicago, Illinois, United States
1182.17.111 Boehringer Ingelheim Investigational Site
🇺🇸Boston, Massachusetts, United States
1182.17.114 Boehringer Ingelheim Investigational Site
🇺🇸San Diego, California, United States
1182.17.1 Boehringer Ingelheim Investigational Site
🇺🇸Indianapolis, Indiana, United States
1182.17.53 Boehringer Ingelheim Investigational Site
🇺🇸Durham, North Carolina, United States
1182.17.135 Boehringer Ingelheim Investigational Site
🇺🇸Rochester, New York, United States
1182.17.7 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.17.99 Boehringer Ingelheim Investigational Site
🇺🇸Philadelphia, Pennsylvania, United States
1182.17.32 University of Kansas School of Medicine - Wichita
🇺🇸Wichita, Kansas, United States
1182.17.51 Boehringer Ingelheim Investigational Site
🇺🇸South Miami, Florida, United States
1182.17.23 Boehringer Ingelheim Investigational Site
🇺🇸Columbia, South Carolina, United States
1182.17.22 Boehringer Ingelheim Investigational Site
🇺🇸Miami, Florida, United States
1182.17.5402 Funcei
🇦🇷Capital Federal, Argentina
1182.17.4301 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1182.17.43 Boehringer Ingelheim Investigational Site
🇺🇸Washington, District of Columbia, United States
1182.17.910 Sunnybrook & Women's College Health Science Centre
🇨🇦Toronto, Ontario, Canada
1182.17.3201 Boehringer Ingelheim Investigational Site
🇧🇪Bruxelles, Belgium
1182.17.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde
🇧🇷Nova Iguaçu - Rio de Janeiro - RJ, Brazil
1182.17.903 Montreal Chest Institute, McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
1182.17.33008 Hôpital de l'Hôtel Dieu
🇫🇷Lyon cedex 2, France
1182.17.33022 Hôpital Européen Georges Pompidou
🇫🇷Paris cedex 15, France
1182.17.902 Downtown Infectious Diseases Clinic
🇨🇦Vancouver, British Columbia, Canada
1182.17.901 Division of Infectious Diseases
🇨🇦Ottawa, Ontario, Canada
1182.17.87 Boehringer Ingelheim Investigational Site
🇺🇸Norwalk, Connecticut, United States
1182.17.126 Boehringer Ingelheim Investigational Site
🇺🇸Fort Lauderdale, Florida, United States
1182.17.5405 Dpto. de Enfermedades infecciosas (Pabellón 22)
🇦🇷Capital Federal, Argentina
1182.17.5406 Pabellón de Clínicas 2° Piso
🇦🇷Capital Federal, Argentina
1182.17.5508 I.I. Emilio Ribas
🇧🇷Cerqueira César, São Paulo - SP, Brazil
1182.17.11 Boehringer Ingelheim Investigational Site
🇺🇸Memphis, Tennessee, United States
1182.17.52 Boehringer Ingelheim Investigational Site
🇺🇸Vero Beach, Florida, United States
1182.17.34 ID Care, Inc.
🇺🇸Hillsborough, New Jersey, United States
1182.17.112 Boehringer Ingelheim Investigational Site
🇺🇸Washington, District of Columbia, United States
1182.17.59 Boehringer Ingelheim Investigational Site
🇺🇸Las Vegas, Nevada, United States
1182.17.3209 Instituut Tropische Geneeskunde
🇧🇪Antwerpen, Belgium
1182.17.3202 Boehringer Ingelheim Investigational Site
🇧🇪Bruxelles, Belgium
1182.17.5502 Farmácia do Instituto de Pesquisa Evandro Chagas
🇧🇷Manguinhos - Rio de Janeiro - RJ, Brazil
1182.17.5504 Enfermaria de MI
🇧🇷São Paulo - SP, Brazil
1182.17.914 Montreal General Hospital - McGill University Health Centre
🇨🇦Monteal, Quebec, Canada
1182.17.33019 Hôpital Saint André
🇫🇷Bordeaux cedex, France
1182.17.33020 Hôpital Côte de Nacre
🇫🇷Caen cedex 5, France
1182.17.33023 Hôpital Edouard Herriot
🇫🇷Lyon cedex 3, France
1182.17.4909 Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
1182.17.3007 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1182.17.118 Early Intervention Program (EIP) Clinic
🇺🇸Camden, New Jersey, United States
1182.17.00336 Hôpital Hôtel Dieu
🇫🇷Nantes cedex 1, France
1182.17.5401 Fundacion Huesped
🇦🇷Capital Federal, Argentina
1182.17.5404 Infectología
🇦🇷Capital Federal, Argentina
1182.17.3207 Boehringer Ingelheim Investigational Site
🇧🇪Gent, Belgium
1182.17.5509 (Unidade de Testes Terapêuticos)
🇧🇷Cidade Nova - Rio de Janeiro - RJ, Brazil
1182.17.5506 Centro de Referência e Treinamento - DST/AIDS
🇧🇷Vila Mariana, Sao Paulo - SP, Brazil
1182.17.33011 Hôpital Pellegrin
🇫🇷Bordeaux cedex, France
1182.17.00331 Hôpital Tenon
🇫🇷Paris cedex 20, France
1182.17.33016 Hôpital Civil
🇫🇷Strasbourg cedex, France
1182.17.4906 ID-Ambulanz Klinikum Dortmund
🇩🇪Dortmund, Germany
1182.17.4905 Universitätsklinik Köln
🇩🇪Köln, Germany
1182.17.3004 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1182.17.0411 Presidio Ospedaliero "A. Manzoni"
🇮🇹Lecco, Italy
1182.17.0388 Ospedale A. Cotugno
🇮🇹Napoli, Italy
1182.17.0398 Ospedale Amedeo di Savoia
🇮🇹Torino, Italy
1182.17.5201 Centro Médico La Raza IMSS
🇲🇽Col. La Raza, Mexico, Mexico
1182.17.5203 Hospital Civil Nuevo de Guadalajara
🇲🇽Guadalajara, Mexico
1182.17.3502 Hospital Condes Castro Guimarães
🇵🇹Cascais, Portugal
1182.17.905 Canadian Immunodeficiency Research Collaborative Inc.
🇨🇦Toronto, Ontario, Canada
1182.17.0395 Azienda Policlinico Umberto I
🇮🇹Roma, Italy
1182.17.915 Clinique medicale l'Actuel
🇨🇦Montreal, Quebec, Canada
1182.17.33007 Hôpital Antoine Beclere
🇫🇷Clamart, France
1182.17.33013 Hôpital Sainte Marguerite
🇫🇷Marseille cedex 9, France
1182.17.33024 Groupe Hospitalier Cochin
🇫🇷Paris cedex 14, France
1182.17.4907 Medizinische Poliklinik
🇩🇪München, Germany
1182.17.4915 Klinium Natruper Holz
🇩🇪Osnabrück, Germany
1182.17.3002 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1182.17.3003 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1182.17.0384 Azienda Ospedaliera Arcispedale S. Anna
🇮🇹Ferrara, Italy
1182.17.0397 Ospedale San Martino
🇮🇹Genova, Italy
1182.17.0394 IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
1182.17.0387 Ospedale Amedeo di Savoia
🇮🇹Torino, Italy
1182.17.3101 Boehringer Ingelheim Investigational Site
🇳🇱Amsterdam, Netherlands
1182.17.3105 Boehringer Ingelheim Investigational Site
🇳🇱Nijmegen, Netherlands
1182.17.202 Boehringer Ingelheim Investigational Site
🇳🇱Rotterdam, Netherlands
1182.17.4101 DIM / Abteilung für Infektiologie
🇨🇭Basel, Switzerland
1182.17.33014 Hôpital Saint Antoine
🇫🇷Paris, France
1182.17.5501 Hospital Dia
🇧🇷Sacoma - São Paulo - SP, Brazil
1182.17.5510 Casa de AIDS
🇧🇷São Paulo, SP, Brazil
1182.17.33012 Hôpital de la Conception
🇫🇷Marseille cedex 5, France
1182.17.33010 Hôpital de l'Archet
🇫🇷Nice cedex 3, France
1182.17.33018 Hôpital de Pontchaillou
🇫🇷Rennes cedex 9, France
1182.17.33017 Hôpital Brabois Adultes
🇫🇷Vandoeuvre les Nancy, France
1182.17.4911 Arzt für Innere Medizin
🇩🇪Aachen, Germany
1182.17.4912 Universitätsklinikum Düsseldorf
🇩🇪Düsseldorf, Germany
1182.17.4923 Facharzt für Innere Medizin,
🇩🇪Mannheim, Germany
1182.17.4910 MUC Research GmbH
🇩🇪München, Germany
1182.17.4921 Arzt für Allgemeinmedizin
🇩🇪Stuttgart, Germany
1182.17.4103 DIM / Abteilung für Infektiologie
🇨🇭St. Gallen, Switzerland
1182.17.913 McMaster University Medical Centre
🇨🇦Hamilton, Ontario, Canada
1182.17.4901 Epimed GmbH c/o
🇩🇪Berlin, Germany
1182.17.4902 Charite, Campus Virchow-Klinikum
🇩🇪Berlin, Germany
1182.17.33021 Hôpital Paul Brousse
🇫🇷Villejuif cedex, France
1182.17.4918 Rheinische Friedrich-Wilhelm-Universität
🇩🇪Bonn, Germany
1182.17.4914 Arzt für Innere Medizin
🇩🇪Düsseldorf, Germany
1182.17.4904 Universitätsklinikum Essen
🇩🇪Essen, Germany
1182.17.4930 Universitätsklinikum Freiburg
🇩🇪Freiburg/Breisgau, Germany
1182.17.4928 Facharzt für Innere Medizin/Rheumatologie
🇩🇪Freiburg, Germany
1182.17.4920 Abteilung Klinische Immunologie
🇩🇪Hannover, Germany
1182.17.4926 Internist
🇩🇪Köln, Germany
1182.17.3001 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1182.17.0386 Policlinico Universitario
🇮🇹Modena, Italy
1182.17.4104 Département de médicine interne Div. Des maladies infectieus
🇨🇭Genève, Switzerland
1182.17.0389 Reparto Malattie Infettive
🇮🇹Macerata, Italy
1182.17.75 Boehringer Ingelheim Investigational Site
🇺🇸Phoenix, Arizona, United States
1182.17.37 Boehringer Ingelheim Investigational Site
🇺🇸San Francisco, California, United States
1182.17.58 Boehringer Ingelheim Investigational Site
🇺🇸San Francisco, California, United States
1182.17.96 Boehringer Ingelheim Investigational Site
🇺🇸San Francisco, California, United States
1182.17.115 Boehringer Ingelheim Investigational Site
🇺🇸Detroit, Michigan, United States
1182.17.6 Boehringer Ingelheim Investigational Site
🇺🇸Detroit, Michigan, United States
1182.17.9 Boehringer Ingelheim Investigational Site
🇺🇸Oklahoma City, Oklahoma, United States
1182.17.18 Vanderbilt AIDS Clinical Trials Center
🇺🇸Nashville, Tennessee, United States
1182.17.4411 Boehringer Ingelheim Investigational Site
🇬🇧Liverpool, United Kingdom
1182.17.125 Boehringer Ingelheim Investigational Site
🇺🇸Tampa, Florida, United States
1182.17.86 Boehringer Ingelheim Investigational Site
🇺🇸Bethesda, Maryland, United States
1182.17.100 Boehringer Ingelheim Investigational Site
🇺🇸Milwaukee, Wisconsin, United States
1182.17.39 MDS Pharma Services
🇺🇸Phoenix, Arizona, United States
1182.17.60 Boehringer Ingelheim Investigational Site
🇺🇸Fountain Valley, California, United States
1182.17.106 Boehringer Ingelheim Investigational Site
🇺🇸Los Angeles, California, United States
1182.17.69 Boehringer Ingelheim Investigational Site
🇺🇸Macon, Georgia, United States
1182.17.128 Boehringer Ingelheim Investigational Site
🇺🇸San Diego, California, United States
1182.17.40 Tower ID Medical
🇺🇸Los Angeles, California, United States
1182.17.47 University of Southern California
🇺🇸Los Angeles, California, United States
1182.17.65 Boehringer Ingelheim Investigational Site
🇺🇸Washington, District of Columbia, United States
1182.17.50 Boehringer Ingelheim Investigational Site
🇺🇸Santa Fe, New Mexico, United States
1182.17.92 Boehringer Ingelheim Investigational Site
🇺🇸Tacoma, Washington, United States
1182.17.105 Pollari Medical Group
🇺🇸New York, New York, United States
1182.17.122 Boehringer Ingelheim Investigational Site
🇺🇸Houston, Texas, United States
1182.17.131 Boehringer Ingelheim Investigational Site
🇺🇸Miami, Florida, United States
1182.17.36 Boehringer Ingelheim Investigational Site
🇺🇸Evanston, Illinois, United States
1182.17.136 Boehringer Ingelheim Investigational Site
🇺🇸Chicago, Illinois, United States
1182.17.77 Boehringer Ingelheim Investigational Site
🇺🇸Atlanta, Georgia, United States
1182.17.30 Boehringer Ingelheim Investigational Site
🇺🇸Portland, Maine, United States
1182.17.5 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.17.103 Boehringer Ingelheim Investigational Site
🇺🇸Mount Vernon, New York, United States
1182.17.24 Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
1182.17.93 Boehringer Ingelheim Investigational Site
🇺🇸East Orange, New Jersey, United States
1182.17.79 Boehringer Ingelheim Investigational Site
🇺🇸Albany, New York, United States
1182.17.3 Division of Infectious Diseases
🇺🇸New York, New York, United States
1182.17.134 Summa Health System
🇺🇸Akron, Ohio, United States
1182.17.42 Beth Israel Medical Center
🇺🇸New York, New York, United States
1182.17.54 Boehringer Ingelheim Investigational Site
🇺🇸Huntersville, North Carolina, United States
1182.17.68 Boehringer Ingelheim Investigational Site
🇺🇸Houston, Texas, United States
1182.17.97 Boehringer Ingelheim Investigational Site
🇺🇸San Antonio, Texas, United States
1182.17.5403 consultorio externo "PETS"
🇦🇷Capital Federal, Argentina
1182.17.10 Boehringer Ingelheim Investigational Site
🇺🇸Annandale, Virginia, United States
1182.17.407 Holdsworth House General Practice
🇦🇺Darlinghurst, New South Wales, Australia
1182.17.404 Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
1182.17.403 Albion Street Clinic
🇦🇺Surry Hills, New South Wales, Australia
1182.17.4505 Boehringer Ingelheim Investigational Site
🇩🇰Aarhus N, Denmark
1182.17.4504 Boehringer Ingelheim Investigational Site
🇩🇰Odense, Denmark
1182.17.3210 Centre Hospitalier de Luxembourg
🇧🇪Luxembourg, Belgium
1182.17.5511 Universidade Federal da Bahia
🇧🇷Canela - Salvador - BA, Brazil
1182.17.5505 Instituto A-Z de Pesquisa e Ensino da PUC
🇧🇷Mercês - Curitiba - PR, Brazil
1182.17.713 Hospital Universitario Vírgen del Rocío
🇪🇸Sevilla, Spain
1182.17.720 Hospital La Fe
🇪🇸Valencia, Spain
1182.17.4406 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1182.17.710 Hospital Gregorio Maranon
🇪🇸Madrid, Spain
1182.17.904 Clinique Medicale Du Quartier Latin
🇨🇦Montreal, Quebec, Canada
1182.17.00335 Hôpital Bichat Claude Bernard
🇫🇷Paris cedex 18, France
1182.17.00333 Hôpital Saint Louis
🇫🇷Paris, France
1182.17.00334 Hôpital de la Pitié Salpêtrière
🇫🇷Paris, France
1182.17.00332 Hôpital du Chalucet
🇫🇷Toulon, France
1182.17.4908 Universitätskliniken Erlangen
🇩🇪Erlangen, Germany
1182.17.4924 Klinikum der J. W.-Goethe-Universität
🇩🇪Frankfurt/Main, Germany
1182.17.4931 IPM Study Center GmbH
🇩🇪Hamburg, Germany
1182.17.4929 Universitätsklinikum Eppendorf
🇩🇪Hamburg, Germany
1182.17.3010 Boehringer Ingelheim Investigational Site
🇬🇷Patras, Greece
1182.17.3009 Boehringer Ingelheim Investigational Site
🇬🇷Thessaloniki, Greece
1182.17.0409 Ospedale Santa Maria Annunziata
🇮🇹Antella (fi), Italy
1182.17.0413 Ospedale di Circolo di Busto
🇮🇹Busto Arsizio (va), Italy
1182.17.0412 S.C. Malattie Infettive
🇮🇹Genova, Italy
1182.17.4405 Boehringer Ingelheim Investigational Site
🇬🇧Brighton, United Kingdom
1182.17.0419 I Cattedra Malattie Infettive
🇮🇹Roma, Italy
1182.17.0415 U.O.A. Malattie Infettive B
🇮🇹Torino, Italy
1182.17.5206 Centro Medico San Vicente
🇲🇽Monterrey, N.l., Mexico, Mexico
1182.17.4407
🇬🇧Portsmouth, United Kingdom
1182.17.714 Hospital General Universitario de Valencia
🇪🇸Valencia, Spain
1182.17.705 Hospital Germans Trias i Pujol
🇪🇸Badalona, Spain
1182.17.0393 Fondazione Centro S. Raffaele del Monte Tabor
🇮🇹Milano, Italy
1182.17.3108 Boehringer Ingelheim Investigational Site
🇳🇱Groningen, Netherlands
1182.17.717 Hospital Clínico Universitario Vírgen de la Victoria
🇪🇸Malaga, Spain
1182.17.701 Hospital Clínico y Provincial de Barcelona
🇪🇸Barcelona, Spain
1182.17.4408 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1182.17.4102 Departement für Innere Medizin
🇨🇭Zürich, Switzerland
1182.17.4414 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1182.17.132 Boehringer Ingelheim Investigational Site
🇺🇸Tampa, Florida, United States
1182.17.76 Boehringer Ingelheim Investigational Site
🇺🇸Tampa, Florida, United States
1182.17.63 Boehringer Ingelheim Investigational Site
🇺🇸Boston, Massachusetts, United States
1182.17.704 Hospital Ramón y Cajal.
🇪🇸Madrid, Spain
1182.17.703 Hospital 12 de Octubre
🇪🇸Madrid, Spain
1182.17.712 Hospital Clínico San Carlos
🇪🇸Madrid, Spain
1182.17.718 Complejo Hospitalario Xeral - Cíes
🇪🇸Vigo, Spain
1182.17.15 Boehringer Ingelheim Investigational Site
🇺🇸Los Angeles, California, United States
1182.17.46 Boehringer Ingelheim Investigational Site
🇺🇸Los Angeles, California, United States
1182.17.8 Boehringer Ingelheim Investigational Site
🇺🇸Fort Myers, Florida, United States
1182.17.129 Boehringer Ingelheim Investigational Site
🇺🇸Sarasota, Florida, United States
1182.17.102 Boehringer Ingelheim Investigational Site
🇺🇸Lexington, Kentucky, United States
1182.17.130 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.17.94 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.17.31 Boehringer Ingelheim Investigational Site
🇺🇸Stony Brook, New York, United States
1182.17.95 Boehringer Ingelheim Investigational Site
🇺🇸Cincinnati, Ohio, United States
1182.17.116 Boehringer Ingelheim Investigational Site
🇺🇸Dallas, Texas, United States
1182.17.110 Boehringer Ingelheim Investigational Site
🇺🇸Philadelphia, Pennsylvania, United States
1182.17.16 Nelson-Tebedo Clinic
🇺🇸Dallas, Texas, United States
1182.17.142 Boehringer Ingelheim Investigational Site
🇺🇸Dallas, Texas, United States
1182.17.405 AIDS Research Initiative
🇦🇺DarlingHurst, New South Wales, Australia
1182.17.402 Taylor Square Private Clinic
🇦🇺Darlinghurst, New South Wales, Australia
1182.17.401 St. Vincent's Hospital
🇦🇺Darlinghurst, New South Wales, Australia
1182.17.408 407 Doctors Pty Ltd.
🇦🇺Darlinghurst, New South Wales, Australia
1182.17.5503 Instituto de Infectologia Emílio Ribas
🇧🇷São Paulo - SP, Brazil
1182.17.4501 Boehringer Ingelheim Investigational Site
🇩🇰Copenhagen Ø, Denmark
1182.17.4502 Boehringer Ingelheim Investigational Site
🇩🇰Hvidovre, Denmark
1182.17.4916 Medizinisches Versorgungszentrum Hamburg
🇩🇪Hamburg, Germany
1182.17.0385 IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
1182.17.4409 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1182.17.64 Boehringer Ingelheim Investigational Site
🇺🇸Orlando, Florida, United States
1182.17.21 Boehringer Ingelheim Investigational Site
🇺🇸Louisville, Kentucky, United States
1182.17.4 Boehringer Ingelheim Investigational Site
🇺🇸Ann Arbor, Michigan, United States
1182.17.62 Boehringer Ingelheim Investigational Site
🇺🇸Kansas City, Missouri, United States
1182.17.4418 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1182.17.4404 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1182.17.74 Boehringer Ingelheim Investigational Site
🇺🇸Springfield, Massachusetts, United States